Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen ...
Cannabidiol (CBD), a non-intoxicating compound in marijuana, “holds substantial promise as an anti-tumor agent” in addition to its other anti-inflammatory properties, a new scientific review ...
Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...
IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young ...
Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for treating glioblastoma, a lethal brain tumor. This approach enabled them to ...
Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...
First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries– Investigator-Initiated (IIT) funded pancreatic and ...
First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries - Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback